company background image
532649 logo

Nectar Lifesciences BSE:532649 Stock Report

Last Price

₹40.57

Market Cap

₹9.1b

7D

1.9%

1Y

20.6%

Updated

02 Jan, 2025

Data

Company Financials

Nectar Lifesciences Limited

BSE:532649 Stock Report

Market Cap: ₹9.1b

532649 Stock Overview

Manufactures and sells pharmaceutical products in India and internationally. More details

532649 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 56.8% below our estimate of its fair value

Became profitable this year

Risk Analysis

Earnings have declined by 7.2% per year over past 5 years

Interest payments are not well covered by earnings


My Notes

Capture your thoughts, links and company narrative

Nectar Lifesciences Limited Competitors

Wanbury

BSE:524212

₹9.8b

Albert David

BSE:524075

₹7.7b

NGL Fine-Chem

BSE:524774

₹11.2b

Ind-Swift Laboratories

NSEI:INDSWFTLAB

₹6.6b

Price History & Performance

Summary of share price highs, lows and changes for Nectar Lifesciences
Historical stock prices
Current Share Price₹40.57
52 Week High₹56.39
52 Week Low₹26.20
Beta1.11
1 Month Change18.45%
3 Month Change-3.43%
1 Year Change20.64%
3 Year Change31.29%
5 Year Change213.52%
Change since IPO56.79%

Recent News & Updates

Recent updates

Shareholder Returns

532649IN PharmaceuticalsIN Market
7D1.9%3.1%0.5%
1Y20.6%36.2%17.4%

Return vs Industry: 532649 underperformed the Indian Pharmaceuticals industry which returned 36.2% over the past year.

Return vs Market: 532649 exceeded the Indian Market which returned 17.4% over the past year.

Price Volatility

Is 532649's price volatile compared to industry and market?
532649 volatility
532649 Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.1%

Stable Share Price: 532649 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 532649's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19951,686Amit Chadahwww.neclife.com

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.

Nectar Lifesciences Limited Fundamentals Summary

How do Nectar Lifesciences's earnings and revenue compare to its market cap?
532649 fundamental statistics
Market cap₹9.09b
Earnings (TTM)₹107.27m
Revenue (TTM)₹16.79b

84.8x

P/E Ratio

0.5x

P/S Ratio

Is 532649 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
532649 income statement (TTM)
Revenue₹16.79b
Cost of Revenue₹11.69b
Gross Profit₹5.11b
Other Expenses₹5.00b
Earnings₹107.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.48
Gross Margin30.40%
Net Profit Margin0.64%
Debt/Equity Ratio58.4%

How did 532649 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 18:17
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nectar Lifesciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Naveed MD.FirstCall Research